Alkermes plc (ALKS) Morgan Stanley Global Healthcare Conference Transcript September 11, 2012 10:55 AM ET Executives Richard Pops - Chairman and CEO Rebecca Peterson - Investor Relations Analysts David Friedman - Morgan Stanley PresentationDavid Friedman - Morgan Stanley
All right. So, as all of you know, since you’re in the room, the next company is Alkermes. I just need to mention that we need to refer you to any disclaimers at morganstanley.com/researchdisclosures. And it’s my pleasure to welcome Richard Pops, who is the Chairman and CEO; and also Rebecca Peterson, who runs Investor Relations. And Richard has been CEO of the company since he joined over 20 years ago and he has led the recent successful merger with Elan Drug Technologies which closed in May of last year, and it’s a great opportunity to have you with us today. So thanks for joining. I thought that I turn it over to you to provide some brief opening remarks and then we’ll go into Q&A. Richard Pops Perfect. Thanks everybody. Thanks for having us. So actually that, the transaction with Elan closed September 16th of last year. So we were just -- this is the one year anniversary of what would turned out to be a merger that made a lot of sense and it made sense looking at it from prospectively and I think, now with one year under our belt, its performing exactly the way we would have hoped, if it could. So 33,000 feet, what we’re so excited about at this moment for this company is this combination of the financial here and now with the exclusive potential of the pipeline and not a notional pipeline, not an early pipeline, but a late pipeline.